Papers/PMID:34414904
Correlation between serum pro inflammatory cytokines and clinical scores of knee osteoarthritic patients using resveratrol as a supplementary therapy with meloxicam.
Indian journal of pharmacology2021The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
resveratrol — increases knee injury and Osteoarthritis Outcome Score (KOOS)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“In Table 2, the administration of resveratrol improves significantly (P < 0.05) both KOOS and WOMAC total scores at the end of the treatment, compared with baseline values and those reported in the control group postintervention.”
Quoted verbatim from Correlation between serum pro inflammatory cytokines and clinical scores of knee osteoarthritic patients using resveratrol as a supplementary therapy with meloxicam.. - Study
- RCT
- Duration
- 3 months
- Dose
- 500 mg/day
- Population
- Adults with painful knee osteoarthritis; resveratrol 500 mg/day plus meloxicam 15 mg/day versus placebo capsule plus meloxicam 15 mg/day (meloxicam in both arms)
Correlation between serum pro inflammatory cytokines and clinical scores of knee osteoarthritic patients using resveratrol as a supplementary therapy with meloxicam.2021PMID:34414904Permalink